JavaScript Menu, DHTML Menu Powered By Milonic

 

  Young smiling boy Medication can be important in the treatment of fragile X related behavior problems
gray picture on left of breadcrumbs

 

TELL A FRIEND

References: T

  • Thomaidis, L., E. Kaderoglou, M. Stefou, S. Damaniou, and C. Bakoula. 2000. Does early intervention work? A controlled trial. Infant Young Child. 12:17.
  • Thompson, S., and J. M. Rey. 1995. Functional enuresis: Is Desmopressin the answer? J. Am. Acad. Child Adolesc. Psychiatry 34:266-271.
  • Thomsen, P. H. 1997. Child and adolescent obsessive-compulsive disorder treated with citalopram: Findings from an open trial of 23 cases. J. Child Adolesc. Psychopharmacol. 7:157-166.
  • Tirosh, E., and Z. Borochowitz. 1992. Sleep apnea in fragile X syndrome. Am. J. Med. Genet. 43:124-127.
  • Tirosh, E., Y. Tal, and M. Jaffe. 1995. CPAP treatment of obstructive sleep apnoea and neurodevelopmental deficits. Acta Paediatr. 84:791-794.
  • Torrioli, M. G., S. Vernacotola, P. Mariotti, E. Bianchi, M. Calvani, A. De Gaetano, P. Chiurazzi, and G. Neri. 1999. Double-blind, placebo-controlled study of l-acetylcarnitine for the treatment of hyperactive behavior in fragile X syndrome [letter]. Am. J. Med. Genet. 87:366-368.
  • Tranfaglia, M. R. 2000. A medication guide for fragile X syndrome, version 3.1. West Newbury, Mass.: FRAXA Research Foundation.
  • Trimble, M. R. 1987. Anticonvulsant drugs and cognitive function: A review of the literature. Epilepsia 28 (suppl. 3): S37-S45.
  • Turk, J. 1992. Fragile X syndrome and folic acid. In R. J. Hagerman and P. McKenzie (eds.), 1992 International Fragile X Conference proceedings. Dillon, Colo.: National Fragile X Foundation and Spectra Publishing, pp. 195-200.
     

This article is not intended to give medical advice for individual cases.  Any change in medical treatment should be done in consultation with appropriate medical personnel. This article is written for medical professionals.  Some of the terms will be unfamiliar to those who are not trained in medical fields.

*This article is from the chapter on treatment in the 3rd edition of Fragile X Syndrome: Diagnosis, Treatment, and Research edited by Randi Jenssen Hagerman, M.D. and Paul Hagerman, M.D., Ph.D., to be published May 2002.  It is included with permission from The Johns Hopkins University Press. References to other chapters refer to chapters in the book which are not included as part of this website.

The complete 3rd edition of Fragile X Syndrome: Diagnosis, Treatment, and Research can be ordered from the National Fragile X Foundation by calling 1-800-688-8765 or from The Johns Hopkins University Press at 1-800-537-5487.

Medical Follow-up   Pharmacotherapy   Future Prospects
Outline   Medications   Medical Conditions
References: A, B, C, D, EF, G, H, IJ, K, L, M, NOP, QR, S, T, UVWXYZ
 

back to homehow to navigatesite map creditsprivacycontact usdisclaimer

© copyright 1998-2008 NFXF